Special Issue

The Molecular Targeting of Glioblastoma: Drug Discovery and Therapies

Message from the Guest Editor

Among the most lethal cancer types, glioblastoma still holds a prominent position and represents a tremendous challenge for physicians, patients and scientists. A number of therapeutic strategies have been developed, but results, in terms of life expectancy, are far from the desired objectives. For this reason, the research for new molecular targets is increasingly pressing. Gene amplification, mutation and methylation represent research fields in glioblastoma that continuously provide new perspectives for therapy. Additionally, molecular targeting by integrin receptors has, in recent years, given rise to new hopes. This Special Issue of the Journal of Personalized Medicine aims to cover the current most advanced therapies, with a particular focus on the discovery of new potential molecular targets and related forthcoming therapies. Special attention will be devoted to the experimental models currently used in drug discovery and to their potential application in glioblastoma research.

Guest Editor

Dr. Mayra Paolillo

Department of Drug Sciences, University of Pavia, Pavia, Italy

Deadline for manuscript submissions

closed (25 July 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



mdpi.com/si/73394

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

